BACKGROUND AND AIM: Helicobacter pylori treatment success rates have varied. A systematic review of the success rate of anti- H pylori therapy in Canada was performed. METHODS: All clinical trials containing Canadian data on the success rate of H pylori treatment were identified using MEDLINE searches, through review of references of retrieved studies and by contacting key investigators. Both randomized and open-label trials were included. Treatment effect size was calculated using a variation of Cochran's Q method. RESULTS: Seventeen papers met the inclusion criteria. Both triple therapies consisting of a proton pump inhibitor (PPI), clarithromycin and either amoxicillin or metronidazole performed well, achieving a success rate of 84% and 82%, respectively. The cure rate of PPI-amoxicillin + metronidazole was 76%. Quadruple therapy consisting of a PPI, bismuth, metronidazole and tetracycline, given for seven to 10 days, achieved a success rate of 87%. CONCLUSION: Both PPI-based triple therapy and quadruple therapy perform well in Canada for the treatment of H pylori infection.
BACKGROUND AND AIM: Helicobacter pylori treatment success rates have varied. A systematic review of the success rate of anti- H pylori therapy in Canada was performed. METHODS: All clinical trials containing Canadian data on the success rate of H pylori treatment were identified using MEDLINE searches, through review of references of retrieved studies and by contacting key investigators. Both randomized and open-label trials were included. Treatment effect size was calculated using a variation of Cochran's Q method. RESULTS: Seventeen papers met the inclusion criteria. Both triple therapies consisting of a proton pump inhibitor (PPI), clarithromycin and either amoxicillin or metronidazole performed well, achieving a success rate of 84% and 82%, respectively. The cure rate of PPI-amoxicillin + metronidazole was 76%. Quadruple therapy consisting of a PPI, bismuth, metronidazole and tetracycline, given for seven to 10 days, achieved a success rate of 87%. CONCLUSION: Both PPI-based triple therapy and quadruple therapy perform well in Canada for the treatment of H pylori infection.
Authors: P Moayyedi; S Soo; J Deeks; B Delaney; A Harris; M Innes; R Oakes; S Wilson; A Roalfe; C Bennett; D Forman Journal: Cochrane Database Syst Rev Date: 2006-04-19
Authors: F Perri; V Festa; R Clemente; M R Villani; M Quitadamo; N Caruso; M L Bergoli; A Andriulli Journal: Am J Gastroenterol Date: 2001-01 Impact factor: 10.864
Authors: S Veldhuyzen Van Zanten; A Farley; N Marcon; R Lahaie; A Archambault; R Hunt; R Bailey; D Owen; J Spénard; A Stiglick; N Aimola; P Colin Journal: Can J Gastroenterol Date: 2000 Jul-Aug Impact factor: 3.522
Authors: J P Gisbert; L González; X Calvet; N García; T López; M Roqué; R Gabriel; J M Pajares Journal: Aliment Pharmacol Ther Date: 2000-10 Impact factor: 8.171
Authors: S Veldhuyzen Van Zanten; K Lauritsen; J C Delchier; J Labenz; C M De Argila; T Lind; H C Treichel; A Stubberöd; A Cockeram; G Hasselgren; L Göthe; M Wrangstadh; P Sinclair Journal: Aliment Pharmacol Ther Date: 2000-12 Impact factor: 8.171
Authors: Anıl Ergin; Hüseyin Çiyiltepe; Aziz Bora Karip; Mehmet Mahir Fersahoğlu; Nuriye Esen Bulut; Ahmet Çakmak; Berk Topaloğlu; Ali Cihan Bilgili; Adnan Somay; İksan Taşdelen; Ümit Akyüz; Kemal Memişoğlu Journal: Obes Surg Date: 2021-06-01 Impact factor: 4.129